| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Acetylcholine iodide (ACh iodide) targets cholinergic receptors (muscarinic receptors [M1-M5] and nicotinic acetylcholine receptors [nAChRs]) [1]
|
|---|---|
| ln Vivo |
- Induction of mammary gland growth in rats: Acetylcholine iodide (ACh iodide) administration induced significant mammary gland development in nulliparous (non-pregnant) rats. After 10 consecutive days of treatment, the wet weight of mammary glands increased by 65% compared to vehicle-treated control rats. Histological examination showed increased ductal branching, alveolar proliferation, and stromal vascularization in mammary tissues [1]
- Maintenance of lactation in rats: In lactating rats, Acetylcholine iodide (ACh iodide) treatment maintained lactation capacity. When administered daily from day 5 to day 15 of lactation, milk yield (measured by pup weight gain) was 42% higher than that of control rats. Pups nursing from treated mothers showed a 38% increase in body weight at weaning compared to control pups [1] - Synergistic effect with mammotropic hormones: Co-administration of Acetylcholine iodide (ACh iodide) with prolactin enhanced mammary growth and lactation. The combined treatment resulted in a 25% greater increase in mammary weight and a 30% higher milk yield compared to Acetylcholine iodide (ACh iodide) alone [1] |
| Animal Protocol |
- Mammary growth induction model: Nulliparous female rats (12-14 weeks old) were randomly divided into control group and Acetylcholine iodide (ACh iodide) treatment group (n=6 per group). The compound was dissolved in sterile physiological saline to prepare an injectable solution. Rats were administered subcutaneously at a dose of 5 mg/kg once daily for 10 consecutive days; the control group received equal volume of physiological saline. At the end of treatment, rats were sacrificed, mammary glands were excised, weighed, and fixed for histological analysis [1]
- Lactation maintenance model: Lactating rats (postpartum day 5) were divided into control and treatment groups (n=5 per group). Acetylcholine iodide (ACh iodide) was dissolved in physiological saline and administered subcutaneously at 3 mg/kg once daily for 10 days (from postpartum day 5 to day 15). Milk yield was indirectly assessed by measuring the cumulative weight gain of litters every 2 days. At weaning (postpartum day 21), pups were weighed, and maternal mammary glands were collected for histological examination [1] - Synergy with prolactin: Nulliparous rats were randomly assigned to three groups: control, Acetylcholine iodide (ACh iodide) alone (5 mg/kg, sc, 10 days), and combined with prolactin (0.5 mg/kg, sc, 10 days). Mammary weight and histological changes were evaluated as above [1] |
| References | |
| Additional Infomation |
Acetylcholine is a neurotransmitter found in neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, some sympathetic effector junctions, and many parts of the central nervous system.
- Chemical classification: Acetylcholine iodide is a quaternary ammonium salt derivative of acetylcholine and is a cholinergic agonist[1] - Mechanism of action: As an exogenous acetylcholine analog, this compound binds to and activates cholinergic receptors (muscarinic and nicotinic receptors) in mammary tissue. This activation promotes downstream signaling pathways, thereby regulating mammary epithelial cell proliferation, ductal branching, and expression of lactation-related genes, thereby inducing mammary growth and maintaining lactation[1] - Research objective: This study used this compound to investigate the role of cholinergic signaling in mammary development and lactation physiology. Its activity indicates that acetylcholine plays a regulatory role in mammary gland growth and lactation, complementing the effects of prolactin and other prolactin-stimulating hormones [1] - Therapeutic potential (historical background): At the time of the research, acetylcholine iodide provided experimental evidence for the development of cholinergic modulators to regulate mammary gland function and had potential applications in veterinary medicine to improve lactation in livestock [1] |
| Molecular Formula |
C7H16INO2
|
|---|---|
| Molecular Weight |
273.1119
|
| Exact Mass |
273.022
|
| CAS # |
2260-50-6
|
| Related CAS # |
Acetylcholine chloride;60-31-1
|
| PubChem CID |
75271
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
161-164 °C
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
11
|
| Complexity |
115
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~366.15 mM)
DMSO : ~100 mg/mL (~366.15 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6615 mL | 18.3076 mL | 36.6153 mL | |
| 5 mM | 0.7323 mL | 3.6615 mL | 7.3231 mL | |
| 10 mM | 0.3662 mL | 1.8308 mL | 3.6615 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
